Home Blog

TANAKA PRECIOUS METAL NEXT Certified as a Special Subsidiary

Marie Jones
-
0

Accelerating TANAKA’s DE&I Initiatives Toward an Environment Where Everyone Can Thrive

TOKYO, Apr 16, 2026 – (JCN Newswire) – TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head Office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) announces that TANAKA PRECIOUS METAL NEXT Co., Ltd., which was established in January 2026, was certified as a special subsidiary under the Act to Facilitate the Employment of Persons with Disabilities on March 30, 2026.

TANAKA has long been committed to fostering an environment where diverse talent can thrive. As part of this, it established TANAKA PRECIOUS METAL NEXT Co., Ltd. in January 2026 and has been working to create a workplace environment where people with disabilities can work while leveraging their individual strengths and to expand employment opportunities. Obtaining this certification marks an important milestone in realizing TANAKA’s vision for the company, aiming to become a company where people can truly derive a sense of joy and satisfaction from working and envision a bright future and new possibilities.

TANAKA PRECIOUS METAL NEXT provides recruitment support and workplace retention support for employees with disabilities across the TANAKA group companies and conducts internal training and awareness-raising activities to promote understanding of the employment of people with disabilities. It also collaborates with government agencies, support organizations, and special needs education schools to examine and establish employment support systems and training methods and is working to develop new businesses that promote the employment of people with disabilities. Its daily business includes assigning tasks such as back-office operations centered on administrative support tasks, and it fosters the creation of an environment where employees can work with peace of mind over the long term.

TANAKA considers the individuality of each employee a source of value and positions diversity, equity, and inclusion (DE&I) as a key management strategy. Based on this policy, it will leverage the functions of TANAKA PRECIOUS METAL NEXT as a special subsidiary to expand the employment opportunities for people with disabilities and promote their retention in the workplace, while continuing to create ongoing employment through collaboration within and outside the group.

Comment from Tomohiro Toi, CEO, TANAKA PRECIOUS METAL NEXT Co., Ltd.

I would like to express my sincere gratitude to everyone who supported us in obtaining the recent certification. We recognize that this certification is a milestone that will enable us to further strengthen the initiatives we have advanced to date. As society’s demands for employment of people with disabilities continue to grow, we will further accelerate our efforts to create a comfortable work environment and new opportunities for thriving so that each employee with a disability working within our group can thrive.

Special subsidiary overview

Company Name TANAKA PRECIOUS METAL NEXT Co., Ltd.
Establish Date January 5, 2026
Executive Officers CEO: Tomohiro Toi
Director: Koichiro Tanaka
Director: Kazuharu Yoshida
Audit Supervisory Board Member: Akihito Sato
Location 2-6-6, Nihonbashi Kayabacho, Chuo-ku, Tokyo 103-0025, Japan
Capital 10 million yen
Business Description – Recruitment support and workplace retention support for employees with disabilities across the TANAKA group companies
– Internal training and awareness-raising activities to promote understanding of the employment of people with disabilities
– Development of employment models in collaboration with government agencies, support organizations, and special needs education schools
– Development of new businesses that promote the employment of people with disabilities
– Back-office operations centered on administrative support tasks (including issuing invoices, replenishing and ordering supplies, and cleaning)

 

About TANAKA

Since its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,778 employees, the group’s consolidated net sales for the fiscal year ended December 2025 were 1,097,813 million yen.

TANAKA PRECIOUS METAL GROUP Co., Ltd.
TANAKA Corporate Website
https://www.tanaka.co.jp/english/

Press inquiries
TANAKA PRECIOUS METAL GROUP Co., Ltd.
https://www.tanaka.co.jp/support/req/other_contact_e/index.html

Press Release: https://www.acnnewswire.com/docs/files/20260416.pdf

Focus Graphite Appoints Former Chief of the Defence Staff General Wayne Eyre to Advisory Board

Marie Jones
-
0
Focus Graphite Appoints Former Chief of the Defence Staff General Wayne Eyre to Advisory Board

General Wayne Eyre to Strengthen Focus Graphite’s Engagement with Defence and Allied Partners Across Critical Supply Chains

Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) (“Focus” or the “Company“), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the appointment of General (Retired) Wayne Eyre, former Chief of the Defence Staff (“CDS“) of the Canadian Armed Forces (“CAF“), to its Advisory Board.

This appointment comes at a time when global security priorities are increasingly shaped by access to secure, reliable supply chains for critical minerals essential to defence systems, energy storage, and advanced technologies.

General Eyre served more than forty (40) years in the CAF, culminating as CDS from 2021 to 2024, where he led Canada’s military through a period of rapidly evolving geopolitical and security challenges. Throughout his career, he commanded at all levels, including the Canadian Army and Military Personnel Command. He served on numerous overseas missions including in the Former Yugoslavia, Afghanistan, and as Deputy Commander of United Nations Command in Korea, where he was the most senior Canadian officer ever permanently stationed in the Asia Pacific region.

He brings extensive operational and institutional experience across U.S. and allied defence systems, including completion of the U.S. Army Special Forces Qualification Course, the U.S. Marine Corps Command and Staff College, the U.S. Marine Corps School of Advanced Warfighting, and the U.S. Army War College. General Eyre holds a Bachelor of Science and three master’s degrees in Military Studies, Operational Studies, and Strategic Studies.

His decorations include the Commander of the Order of Military Merit, the Meritorious Service Cross, and multiple international honours from allied nations, recognizing his leadership and service across the globe. He is currently a Visiting Professor and Senior Fellow at the University of Ottawa’s Graduate School of Public and International Affairs, and continues to advise on global security, defence transformation, and strategic leadership.

In his role with Focus, General Eyre will provide strategic guidance on defence-related applications of graphite, support engagement with allied and NATO-aligned partners, and advise on positioning the Company within evolving North American and allied critical minerals frameworks.

“Our high-quality material and thermal purification process lends itself to defence and advanced systems,” said Dean Hanisch, CEO of Focus Graphite. “General Eyre’s leadership at the highest levels of the Canadian Armed Forces, combined with his deep experience across NATO and allied operations, brings critical insight to our strategy. His perspective will help position Focus Graphite as a trusted supplier supporting defence, energy, and advanced material systems across allied nations.”

“The character of modern security is changing, with supply chains becoming as critical as the systems they support,” said General Wayne Eyre. “Materials like graphite are foundational to energy storage, advanced technologies, and defence readiness. Focus Graphite is well positioned to contribute to strengthening secure, sovereign supply chains, and I look forward to supporting the Company as it advances its role within Canada and across NATO partners.”

This appointment further strengthens Focus Graphite’s positioning at the intersection of critical minerals, defence readiness, and advanced materials development. The Company continues to advance its Lac Knife and Lac Tetepisca projects, alongside downstream processing initiatives, to support a secure and resilient North American supply chain.

About Focus Graphite Advanced Materials Inc.

Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.

Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining – we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.

Our commitment to innovation ensures an eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals – reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.

For more information on Focus Graphite Inc. please visit http://www.focusgraphite.com
LinkedIn: https://www.linkedin.com/company/focus-graphite/
X: https://x.com/focusgraphite

Investors Contact:
Dean Hanisch
CEO, Focus Graphite Inc.
dhanisch@focusgraphite.com
+1 (613) 612-6060

Jason Latkowcer
VP Corporate Development
jlatkowcer@focusgraphite.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could,” “intend,” “expect,” “believe,” “will,” “projected,” “estimated,” and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company’s current beliefs or assumptions as to the outcome and timing of such future events.

In particular, this press release contains forward-looking information regarding, among other things, the anticipated contributions of General Wayne Eyre in his role as an advisor to the Company; the Company’s ability to leverage his experience to support engagement with defence stakeholders, NATO-aligned partners, and allied supply chain initiatives; the growing importance of secure, North American sources of graphite for defence, energy storage, and advanced technologies; and the Company’s plans and objectives for advancing its Lac Knife and Lac Tétépisca projects, downstream processing capabilities, and broader critical minerals strategy.

Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company’s public disclosure documents available under its profile on SEDAR+.

The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292837

3 Years and 11 Months! ‘AI+All-in-One PV Storage’ Sigenergy Listed on HKEX: Fastest IPO Record for a Chinese Enterprise

Marie Jones
-
0

Sigenergy Technology Co., Ltd. (“Sigenergy” or “the company” Stock Code: 06656.HK) officially commenced trading on the Main Board of the Hong Kong Stock Exchange (HKEX) today. As the first “AI + All-in-One PV Storage” company to list on the exchange, Sigenergy has set a new record for the fastest IPO by a Chinese enterprise.

The stock showed strong momentum on its debut, opening at HK$ 581, representing almost an 80% increase over the offer price. Market cap exceeded HK$140 billion. Based on the offer price of HK$324.20 per share, the company raised over HK$4.4 billion in its IPO. If the over-allotment option (greenshoe) is exercised in full, the total proceeds will reach HK$5.06 billion.

A Milestone for the Company, the Beginning for a New Chapter

Founded only 3 years and 11 months ago, Sigenergy’s rapid path to listing reflects its focus on defining new industry standards rather than following short-term market trends. The IPO attracted a prestigious group of cornerstone investors, highlighting the company’s strategic value in the 2026 Hong Kong market.

At the listing ceremony, Mr. Xu Yingtong, Founder and CEO of Sigenergy, together with Mr. Zhang Xianmiao, President of Sigenergy, witnessed this pivotal milestone in the company’s journey.

Mr. Xu Yingtong stated: “Listing marks a new beginning for us. Guided by our ‘AI in All’ mission, we are doubling down on energy storage and accelerating R&D to fortify our competitive edge. Our goal is to ensure that AI translates into tangible value for our customers. As we advance our global expansion and refine our international network, we are proud to share the story of ‘China’s Intelligent Manufacturing’ in the renewable energy sector. We promise to uphold the highest standards of operational excellence, rewarding your trust with exceptional results and building a legacy as a transparent, reliable, and socially responsible enterprise.”

Sigenergy’s cornerstone investors include world-class sovereign wealth funds and asset managers such as Temasek, Goldman Sachs Asset Management, UBS Asset Management, and BNP Paribas Asset Management. Other notable participants include Hillhouse, CPE, Boyu Capital, Gaoyi Asset Management, and Greenwoods Asset Management, alongside insurance and specialized funds like CPIC, ORIX, and Walden International.

This diverse group of high-caliber investors signals a strong market consensus: Sigenergy is recognized as a unique player in the “AI + All-in-One PV Storage” sector, underpinned by proprietary technology, high entry barriers, and predictable growth. Beyond a mere endorsement of the company, this capital influx confirms the market’s conviction that “AI-native” architecture is the definitive standard for next-generation energy storage.

Market confidence is supported by Sigenergy’s rapid scale-up. According to the prospectus, the company’s revenue grew from RMB 58.30 million in 2023 to RMB 9.00 billion in 2025, increased 154.4 times in two years. During this period, gross margins expanded from 31.3% to 50.1%, with an adjusted net margin reaching 35.9%. These figures validate the commercial viability of Sigenergy’s “AI-native” technology path.

Differentiation Through “AI-Native” Technology

Unlike traditional “hardware-first, AI-enabled” peers, the company established a more thorough “AI-native” path by integrating artificial intelligence across product design, manufacturing, and business models, the company has achieved a system that is inherently intelligent and capable of continuous evolution.

Its flagship product, SigenStor, is a five-in-one system that combines an inverter, EV DC charging module, and battery pack into a modular, stackable unit which achieves a deep integration of power electronics, cloud and AI technologies, enhances product performance while delivering a more convenient user experience.

The actual value of system’s “AI-native” capabilities is particularly effective in markets with dynamic electricity pricing. Facing fluctuations on an hourly or even minute-by-minute basis, traditional “charge at low, use at high” strategies based on fixed rules are no longer sufficient. By analyzing real-time prices, weather forecasts, and consumer habits, the system optimizes energy scheduling. In the Swedish market, SigenStor helped users reduce electricity costs by an average of 70.3%, showing the effective translation from AI technology into tangible financial benefits.

Sigenergy continuously strengthens its competitive edge through a “Data-Intelligence” closed-loop. As global install base grows, the system leverages real-world operational data to undergo autonomous learning and optimization. This evolution directly translates into superior economic returns for users, which in turn fosters brand loyalty and higher retention. This data-driven cycle creates a powerful network effect, establishing a formidable, long-term barrier to entry in the Energy AI sector.

Since its launch, SigenStor has established a strong global presence through its unique value proposition. According to Frost & Sullivan, Sigenergy has become the world No.1 provider of stackable distributed PV and storage all-in-one solutions in 2024, securing a 28.6% market share. Further data from SunWiz confirms that in 2025, the company ranked first in the under-1000kWh segment across Australia, Ireland, and South Africa, while maintaining a top-tier position in the UK, Sweden, and the Netherlands. This deep penetration into high-value markets has delivered significant commercial returns and reinforced Sigenergy’s brand equity. As the company expands into the Asia-Pacific and Latin American regions, its growth trajectory remains robust.

To support the trajectory, the company has built a robust manufacturing footprint with production bases in Lingang and Jinqiao, Shanghai, as well as Nantong, Jiangsu. By the end of 2025, the company achieved an annual design capacity of nearly 360,000 inverters and over 5.6 GWh of energy storage batteries. This infrastructure provides a stable foundation for the company’s ongoing global expansion.

The successful HKEX listing marks a significant milestone in Sigenergy’s commitment to innovation and recognizes its substantial growth potential. Entering this new chapter, and with the support of premier institutional investors, Sigenergy will focus on optimizing resource integration and accelerating its global ‘AI + Energy Storage’ strategy. By solidifying its technological leadership and market presence, the company aims to build a sustainable foundation for long-term value creation.

Source: ACN Newswire

GMG Doubles Energy Density of 6 Minute Charging Graphene Aluminium-Ion Battery

Marie Jones
-
0
GMG Doubles Energy Density of 6 Minute Charging Graphene Aluminium-Ion Battery

Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) (“GMG” or the “Company”) is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology (“G+A CELLS”) being developed by GMG and the University of Queensland (“UQ”) under a Joint Development Agreement with Rio Tinto, one of the world’s largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana (“BIC”) in the United States of America.

The GMG G+A CELLS have now demonstrated superior performance characteristics when compared to a representative market leading ultra-fast charging batteries, the Lithium Titanate Oxide (“LTO”) batteries, which can be sold at a premium price of up to US$1200/kWh.1

Figure 1 shows the current energy density of G+A CELLS, based on BIC testing, and shows the doubling in performance (26 to 49 Wh/kg) since the previous announcement in December 20252 and in comparison, to a representative market leading fast charging high power LTO batteries.

Figure 1: Increase in Energy Density for G+A CELLS since December ’25 Update
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure1.jpg

Figure 2 shows the charge and discharge curves for the G+A CELLS when charged in 6 minutes (10C) and 60 minutes (1C). The energy density of the cells for the G+A CELLS when charged in 60 minutes (1C) is now 101 Wh/kg when charging to 100% State of Charge (SOC) which is an increase from 58 Wh/kg from the previous update. This shows the G+A CELLS have a nominal voltage of approximately 3.2 Volts (an increase from 3.0 Volts in the previous update). The G+A CELLS maintained performance over hundreds of cycles at 6-minute fast charging rate (10C).

Figure 2: Battery performance curves of G+A CELLS at 60 min and 6min charge (1C & 10C)
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_001full.jpg

Bob Galyen, GMG Non-Executive Director and former CTO of CATL – the largest battery manufacturer in the world, commented: “With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG’s battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems and or combinatorial systems with multiple battery technologies while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells – it is a new platform that can open markets and use cases that were previously uneconomic or impractical. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology.”

Standard commercial Lithium Nickel Manganese Cobalt (“LNMC”) and Lithium Iron Phosphate (“LFP”) battery cells for electric vehicles and stationary storage are NOT designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).3

GMG has now developed a completely new hybrid electrolyte that is chloride free and non-corrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over hundreds of cycles. The substrate for both the cathode and anode in the G+A CELLS is aluminium foil – which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG’s technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.

GMG believes that it has significantly met the key target specification requirements for use in heavy mobile equipment, as shown in Figure 3, its main targeted use case, including:

– Charging in under 6 minutes;
– Energy density > 100 Wh/kg after 1 hour of charging; and
– Safe (no Lithium).

The next battery development steps include the following activities:
– Test and show cycle life up to 10,000 cycles
– Test and show ambient temperature impacts
– Test and show standard safety testing
– Test and show no thermal battery management system needed

Figure 3: G+A CELLS Battery Use Case – heavy mobile equipment
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure3.jpg

Craig Nicol, GMG Managing Director and CEO, commented: “This is a significant step up from where we were at with battery performance in December 2025 and we see the required performance for our targeted use case being largely met – which means we can start to put together the next stages of the battery maturation program – including partnerships and manufacturing plans.”

GMG management believes that the G+A CELLS can eventually achieve over 160 Wh/kg when charged in 1 hour, and over 80 Wh/kg when charged in 6 minutes with further development of the cathode, anode, electrolyte and component weights.

Figure 4 shows the latest G+A CELLS in pouch format:

Figure 4: Current Multi-Layer G+A CELL
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure4.jpg

Battery Technology Readiness Level

The battery technology readiness level (“BTRL”) of the G+A CELLS remains at Level 4, whilst significantly progressed through this level as shown in Figure 5. GMG is currently in the process of completing the optimization of the electrochemical behaviour for the pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will ultimately progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+A CELLS are the same as those employed to make Lithium-Ion Batteries, though no definitive timeline for achievement can be provided at this time.

Figure 5: Battery Technology Readiness Level (BTRL)
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_004full.jpg

The Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.

Figure 6: Battery Cell Roadmap
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_005full.jpg

Next Steps Toward Commercialisation & Market Applications

Jack Perkowski, GMG Non-Executive Chairman and Director, commented: “I am extremely proud that GMG has progressed its battery to this stage – the Company is getting very close to final commercialisation steps. We look forward to providing further updates as GMG progresses the development of its battery technology.”

The Company continues to see a broad range of potential applications for a completed G+A CELLS – utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:

Figure 7: Market Applications
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_006full.jpg

Currently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells – reducing the weight, cost and complexity relative to using a metal case. Using a plastic battery pack is possible for two main reasons – GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of G+A CELL packs when compared to lithium-ion batteries.

Figure 8: Expected Battery Pack for GMG’s G+A CELLS Pouch Format
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_007full.jpg

Comparison and Market Review: LTO Batteries

As shown in Figure 9 below, the performance of GMG’s G+A CELL technology is already very similar to representative LTO batteries.

Figure 9: Comparison of GMG’s G+A CELLS to Lithium Titanate Oxide (LTO) Battery
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure9.jpg

LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for G+A CELLS are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.

LTO batteries have energy density ranging from 50 – 80 Wh/kg.6 The LTO product is sold globally for use in many applications – with a total of US$5.67 billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 16.9% per annum to an estimated US$ 12.5 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.

Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+A CELLS can be substituted at a substantially lower cost.

– Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.

– Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power “opportunity charges” during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.

– Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.

– Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.

– Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.

– Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 degrees C to +60 degrees C ambient.

– 5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.

– Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.

– 12V starter replacement to Lead acid: GMG’s G+A CELLS battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry’s stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.

– Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe’s Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries’ fast-response profile.

– Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.

About BIC:

BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.

About GMG:

GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, ‘tuneable’ and low/no contaminant graphene suitable for use in clean-technology and other applications.

The Company’s present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning (“HVAC-R”) coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.

In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries (“G+AI Batteries”). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.

GMG’s 4 critical business objectives are:
1. Produce Graphene and improve/scale cell production processes
2. Build Revenue from Energy Savings Products
3. Develop Next-Generation Battery
4. Develop Supply Chain, Partners & Project Execution Capability

For further information please contact:
Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223
Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041

www.graphenemg.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends”, “expects” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or will “potentially” or “likely” occur. This information and these statements, referred to herein as “forward‐looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the pricing of LTO batteries, expectations for GMG G+AI batteries to achieve specification requirements for heavy mobile equipment, the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, stability, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.

Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading “Risk Factors” in the Company’s annual information form dated November 04, 2025 available for review on the Company’s profile at www.sedarplus.ca.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292641

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies

Marie Jones
-
0

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI’s novel Obrion(TM) ADC enabling technologies(GlycOBI(R) and GlycOBI DUO(R)).

OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI’s lead programs, OBI-902 and OBI-904.

We are further advancing precision oncology through our next-generation bispecific (OBI-201) and bispecific, dual-payload (OBI-221) ADCs. These “biology – driven” molecules are designed to overcome tumor heterogeneity and multi-drug resistance-key challenges in current cancer treatment. By incorporating both the GlycOBI® and GlycOBI DUO® platforms, OBI is developing novel and differentiated therapeutics addressing the unmet medical need for patients with difficult-to-treat solid tumors. Additionally, OBI’s robust ADC conjugation platform has proven to consistently deliver product quality and scalability, while enabling expansion into next-generation modalities, including degrader-antibody conjugates (DACs).

These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 17 to 22, 2026 in San Diego, CA. (USA).

“At OBI, we make better ADCs,” said Dr. Ya-Chi Chen, Chief Scientific Officer OBI Pharma. “Our goal is to deliver therapies that not only target tumors more effectively and precisely, but also reduce side effects, giving patients potentially life-changing treatment options.”

Monday, April 20, 2026 (9:00 AM – 12:00 PM)

Title: Overcoming Resistance with OBI-902: Preclinical Evaluation of a Next-Generation TROP2 ADC1

Authors: Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen. OBI Pharma, Inc, Taipei, Taiwan

Session Title: PO. ET07.01 – Quantitative Pharmacology and Translational Modeling
Location: Poster Section 17
Poster Board Number: 6
Abstract Presentation Number: 1818

Title: OBI-904, a Next-Generation Nectin-4-Targeting Exatecan ADC, Demonstrates Enhanced Cytotoxicity and Overcomes Enfortumab Vedotin Resistance2

Authors :Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, Taiwan

Session Title: PO.ET02.02 – Antibody-Drug Conjugates and Linker Engineering 2
Location: Poster Section 13
Poster Board Number: 26
Abstract Presentation Number: 1729

Title: OBI-904, a Glycan-based Site specific Nectin-4-Targeted ADC, Demonstrates Potent and Durable Antitumor Activity with an Improved PK Profile and Overcoming EV-Resistance in Non-Clinical Studies3

Authors: Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, Taiwan

Session Title: PO.ET07.01 – Quantitative Pharmacology and Translational Modeling
Location: Poster Section 17
Poster Board Number: 7
Abstract Presentation Number: 1819

Title: The MET/HER3 Antibody-Drug Conjugate with Dual Payload: A Dual-Target Approach to Eliminate Tumor Escape Mechanisms5

Authors: Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, Taiwan

Session Title: PO.CL.0705 – Targeted Antigen Therapies and Immunity
Location: Poster Section 49
Poster Board Number: 17
Abstract Presentation Number: 2665

Title: Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery6

Authors: Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen .OBI Pharma, Inc., Taipei, Taiwan

Session Title: PO.ET02.02 – Antibody-Drug Conjugates and Linker Engineering 2
Location: Poster Section 13
Poster Board Number : 27
Abstract Presentation Number: 1730

Title: Hydrophilicity-Enhanced Linker Technology Enables Site-Specific Degrader-Antibody Conjugates with Improved Stability and Enhanced Activity7

Authors: Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang. OBI Pharma, Inc., Taipei, Taiwan

Session Title: PO.ET02.02 – Antibody-Drug Conjugates and Linker Engineering 2
Location: Poster Section 13
Poster Board Number: 28
Abstract Presentation Number: 1731

Title: Cell-based payload release highlights design, site, and cell-dependent ratio shifts in dual-payload ADCs8

Authors: Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, Taiwan

Session Title: PO.CH01.06 – Antibodies, Antibody-Drug Conjugates, and Nucleic Acids
Location: Poster Section 38
Poster Board Number: 5
Abstract Presentation Number: 2397

Monday, April 20, 2026 (2:00 PM – 5:00 PM)

Title:TROP2 Upregulation and Interaction with HER2 Mediate Trastuzumab Resistance4

Authors: Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen. OBI Pharma, Inc., Taipei, Taiwan

Session Title: PO.ET03.06 Drug Resistance 1: Antibodies and ADCs
Location: Poster Section 12
Poster Board Number: 18
Abstract Presentation Number: 2972

Tuesday, April 21, 2026 (9:00 AM – 12:00 PM)

Title: Glycan-based site specific ADC Achieves Sustained Tumor Control through Improved Payload Delivery and Immune Activation9

Authors: Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi. OBI Pharma, Inc, Taipei, Taiwan

Session Title: PO.IM02.04 – Adaptive Immunity in Cancer
Location: Poster Section 6
Poster Board Number: 2
Abstract Presentation Number: 4234

Title: Advancing ADC therapeutics with next-generation site-specific glycan conjugation and dual-payload flexibility10

Authors: Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen,Teng-Yi Huang. OBI Pharma, Inc, Taipei, Taiwan

Session Title: PO.ET02.03 – Antibody-Drug Conjugates and Linker Engineering 3
Location: Poster Section 12
Poster Board Number: 1
Abstract Presentation Number: 4423

The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website (www.obipharma.com) beginning on April 18.

1 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/4583
2 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5385
3 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/4588
4 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5030
5 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/4051
6 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5400
7 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5401
8 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/6474
9 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/1311
10 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5403

About OBI Pharma
OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.

OBI’s research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, HYPrOBI®, and the novel irreversible cysteine-conjugation technology ThiOBI® , to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2), which is under Ph1 clinical evaluation, and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). To broaden the applicability of the HYPrOBI® linker technology, OBI has further developed the ThiOBI® technology to enable irreversible cysteine-based conjugation. In addition to its ADC programs, OBI’s assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com.

About OBI-902 and OBI-992
OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.

OBI-902 is a novel site-specific glycan-conjugated ADC using OBI’s proprietary GlycOBI® platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy across multiple tumors, including NSCLC, triple-negative breast cancer (TNBC), and gastric cancer, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the United States Food and Drug Administration (US FDA) on April 30, 2025, received Orphan Drug Designation (ODD) from the US FDA for cholangiocarcinoma on Nov. 16, 2025, and gastric cancer (GC), including gastroesophageal junction cancer (GEJC) on December 5, 2025.The Phase 1/2 Study (NCT07124117) is ongoing, with completion of the Phase 1a portion targeted for 1H 2027.

OBI-992 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload with drug-to-antibody ratio of 4 (DAR 4) via a cysteine conjugated, hydrophilic and enzyme-cleavable linker. OBI-992 remains stable in circulation and delivers this cytotoxic payload to TROP2-expressing tumor cells, leading to tumor cell death while avoiding off-target toxicities.

The US FDA cleared the IND application for OBI-992 in Jan 2024 and subsequently granted Orphan Drug Designation for the treatment of gastric cancer, including GEJC in Aug 2024. The Phase 1/2 Study (NCT06480240) has reached the putative Recommended Phase 2 Dose (pRP2D) and Phase I completion is targeted for 1H 2027.

Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive license to a TROP2 targeting antibody amino acid sequence in all jurisdictions except Mainland China, Hong Kong and Macau. Biosion holds exclusive rights to that antibody sequence in Mainland China, Hong Kong and Macau. OBI holds commercial rights to OBI-992 and OBI-902 in all jurisdictions except Mainland China, Hong Kong and Macau, while Biosion holds commercial rights to OBI-992 and OBI-902 in Mainland China, Hong Kong and Macau.

About OBI-904
OBI-904 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody specifically targeting Nectin-4 (Nectin cell adhesion molecule 4), linked to a potent topoisomerase I inhibitor payload with Drug-to-Antibody Ratio of 8 (DAR8) through OBI’s proprietary GlycOBI® ADC enabling technologies, powered by a dual-function enzyme, EndoSymeOBI®, and a novel linker, HYPrOBI®. It is a potentially first-in-class and best-in-class glycan-based ADC designed to target multiple cancer types that express Nectin-4. Antitumor activity has been shown across several animal disease models, including HNSCC, CRC, TNBC, cervical and sarcoma cancers; OBI-904 has demonstrated a favorable safety profile in a repeat dose toxicity study in monkeys, and is now in the pre-IND stage of development.

About OBI-201
OBI-201 is a TROP2 x HER2 bispecific ADC generated by OBI GlycOBI® ADC enabling technologies conjugated with a topoisomerase I inhibitor. Notably, OBI is the first to demonstrate that HER2 and TROP2 can interact and form a protein complex on the cell surface-a groundbreaking discovery facilitated through collaboration with a specialized AI drug discovery partner. OBI-201 offers several advantages over mono-specific TROP2 or HER2 ADCs. By targeting both antigens, it broadens tumor coverage, especially in cancers with heterogeneous or low expression of either target. Dual targeting can enhance tumor selectivity, binding avidity, and internalization, improving payload delivery to cancer cells while potentially reducing toxicity to normal cells. OBI-201 may overcome resistance associated with downregulation of targets after treatment by certain monospecific ADCs.

Animal studies revealed that OBI-201 demonstrated significantly superior anti-tumor activity compared to single-target ADCs in drug-resistant breast cancer models with extremely low HER2 expression. OBI-201 was able to sustain tumor growth suppression, indicating its potential to overcome multiple drug-resistance mechanisms. OBI-201 is a next-generation bispecific ADC poised to break through the limitations of single-target ADCs, potentially offering patients a more comprehensive and durable treatment option.

About OBI-221
OBI-221 is a Bispecific-Dual Payload ADC (BsDpADC), generated by OBI GlycOBI DUO® technologies, targeting cMET and HER3, conjugated with dual payload of MMAE and topoisomerase I inhibitor.

In clinical practice, EGFR-targeted therapies have become a key strategy for treating non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients. However, tumors often rapidly develop resistance by upregulating cMET and HER3 that, in turn, sustain tumor growth. Moreover, high expressions of cMET and HER3 have been observed in gastric cancer, head and neck cancer, and various other solid tumors, further underscoring the unmet medical needs.

To address this challenge, OBI Pharma leverages its proprietary GlycOBI DUO® platform and HYPrOBI® linker to develop a novel bispecific dual-payload antibody-drug conjugate (BsDpADC)-OBI-221. This therapeutic agent simultaneously targets cMET and HER3 while delivering synergistic cytotoxic agents, effectively combating tumor resistance and heterogeneity. This breakthrough design not only addresses an unmet medical need but also represents a forward-looking strategy for next-generation ADC development.

OBI-221 holds meaningful potential to overcome resistance to existing EGFR-targeted therapies, potentially offering patients more targeted treatment options while delivering substantial clinical value.

About GlycOBI®
OBI has developed a unique glycan-based, site-specific ADC technology (GlycOBI®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug-antibody ratios (DAR)(up to 16). Powered by OBI’s proprietary dual-function enzymatic technology EndoSymeOBI® and its hydrophilic linker technology HYPrOBI®, GlycOBI®, a core component of OBI’s Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs through an efficient, scalable and streamlined two-step, one-pot conjugation process under GMP conditions.

During the conjugation process, GlycOBI® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI’s linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies. Notably, the platform supports the conjugation of both cytotoxic small-molecule inhibitors and highly hydrophobic degraders, expanding its applicability to next-generation modalities such as DACs.

About GlycOBI DUO®
GlycOBI DUO® is a next-generation dual-payload antibody-drug conjugate (ADC) technology built on the GlycOBI® site-specific conjugation platform and its proprietary enzymatic conjugation strategy. It enables the precise and programmable attachment of two distinct payloads to a single antibody with tunable ratios and supports high DAR ratios, including up to DAR24. By combining complementary mechanisms of action, GlycOBI DUO® is designed to enhance antitumor efficacy, address tumor heterogeneity, and improve the overall therapeutic index, with the potential to overcome resistance mechanisms associated with conventional ADCs-representing a promising advancement in next-generation ADC development.

About ThiOBI®
OBI has developed a novel irreversible, cysteine conjugation ADC platform (ThiOBI®) with improved stability, which can apply to any antibodies, linkers, and payloads. OBI’s proprietary ThiOBI® platform including linker technologies (HYPrOBI®) can generate ADCs in different biomolecular formats, including antibody fragments, nanobodies, peptides, and proteins. Furthermore, OBI’s HYPrOBI® linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity and also expanded the half-life of the ADC products. ThiOBI has overcome the limitations of traditional cysteine ADCs and achieved better antitumor activity and stability in various in vivo tests.

GlycOBI®, EndoSymeOBI®, ThiOBI®, HYPrOBI®, and GlycOBI DUO® are registered trademarks of OBI. Obrion™ is a trademark under registration.

Forward-Looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Futures Bureau.

COMPANY CONTACT:
Jukka Muhonen
Executive Director, Business Development
OBI Pharma USA, Inc.
1.617.821.0292
jukkamuhonen@obipharma.com

SOURCE: OBI Pharma USA, Inc.

ASEAN Enterprises Move from AI Experiments to Engineering-Driven Deployment

Marie Jones
-
0
ASEAN Enterprises Move from AI Experiments to Engineering-Driven Deployment

As artificial intelligence adoption accelerates across Southeast Asia, enterprises across the ASEAN region are increasingly establishing structured AI engineering practices to move from experimentation to production-scale deployment.

According to Joseph Bosco, Partner Manager, APJ – Prof Services at Databricks, organisations across ASEAN are recognising that sustainable AI adoption depends not only on advanced models but also on robust engineering foundations that ensure reliability, governance and operational scalability.

“The early phase of AI adoption focused heavily on experimentation and proofs of concept,” Bosco said. “Across Southeast Asia we are now seeing a shift towards AI engineering practices that prioritise data quality, governance and production readiness.”

Markets such as Singapore, Indonesia, Vietnam, Malaysia and Thailand are witnessing strong momentum in enterprise AI adoption as organisations modernise their data infrastructure and invest in advanced analytics capabilities.

Industry experts note that AI engineering is becoming a critical discipline that connects AI innovation with enterprise operations. This includes building scalable data pipelines, managing machine learning lifecycle processes and integrating AI systems into business workflows.

“Building a model is only one part of the challenge,” Bosco said. “The real work lies in creating reliable data pipelines, managing model lifecycle and embedding AI into operational systems.”

Across ASEAN, many enterprises continue to manage complex data environments spanning legacy systems, multiple cloud platforms and software-as-a-service applications. Consolidating these fragmented data sources into unified platforms is increasingly seen as a prerequisite for scaling AI initiatives.

Technology partners and consulting firms across the region are responding by developing dedicated AI engineering practices that combine expertise in data engineering, machine learning, generative AI and governance frameworks.

These capabilities are already being applied across key sectors including financial services, telecommunications, and manufacturing.

Bosco noted that Southeast Asia’s rapidly expanding data economies are creating a particularly dynamic environment for AI engineering talent and innovation.

“As organisations across ASEAN continue to invest in data transformation, AI engineering will become an essential capability that enables enterprises to operationalise AI safely and effectively,” he said.

Exito Media Concepts Announces the 46th Edition of the Digital Transformation Summit Malaysia 2026

Marie Jones
-
0
Exito Media Concepts Announces the 46th Edition of the Digital Transformation Summit Malaysia 2026

Smart Investments. Scalable Tech. Stronger Security

Exito Media Concepts today announced the 46th Edition of the Digital Transformation Summit Malaysia 2026, convening on 23rd April 2026 at the Hyatt Regency Kuala Lumpur Midtown. The summit will bring together more than 200 C-Level executives, technology directors, and government leaders to address the strategic and operational imperatives shaping Malaysia’s next phase of digital growth.

Now in its 46th edition and part of a series spanning 11+ countries, the summit has established itself as one of Asia Pacific’s most consequential forums for enterprise technology leadership.

The Strategic Context: Malaysia’s Digital Economy at a Critical Juncture

Malaysia’s digital economy is undergoing a structural shift. Driven by targeted government-led initiatives and accelerating enterprise adoption of artificial intelligence, the Internet of Things, and Web 3.0, organizations across every sector are fundamentally reimagining how they operate, compete, and deliver value.

The opportunity is significant. Yet the path to enterprise-wide transformation demands more than technology investment — it requires navigating complex cybersecurity environments, integrating legacy infrastructure with modern digital architecture, developing organizational capabilities at pace, and embedding a culture of innovation that sustains long-term resilience. For Malaysia’s business leadership, strategic clarity has never been more consequential.

The Digital Transformation Summit Malaysia 2026 is designed precisely for this inflection point.

Enterprise Transformation in Practice

The business case for bold digital action is already being written across Malaysia. A leading domestic enterprise recently undertook a comprehensive digital transformation initiative — transitioning to a cloud-first infrastructure supported by advanced data analytics and AI capabilities.

The results were measurable and material: automating key operational processes delivered significant gains in efficiency and organizational agility. The concurrent deployment of robust cybersecurity frameworks ensured data integrity and regulatory compliance. Simultaneously, structured workforce upskilling programmes enabled teams to perform with confidence in an evolving technology environment.

The outcome: improved business performance, deeper customer engagement, and a materially stronger competitive position within Malaysia’s digital economy. It is precisely this calibre of real-world insight that the Summit is built to surface and scale.

Event Overview

The 46th Edition of the Digital Transformation Summit Malaysia 2026 is part of a globally recognized series of events hosted across 11+ countries. This edition will convene more than 200 C-Level Executives, Directors, Heads of Technology, Government leaders, and digital transformation leaders from across industries.

Through expert-led keynotes, panel discussions, and real-world case studies, the summit will highlight innovative strategies, emerging technologies, and actionable insights that empower organizations to drive digital growth and operational excellence.

Date: 23rd April 2026
Time: 09:00 AM to 05:00 PM
Venue: Hyatt Regency Kuala Lumpur Midtown
Website: https://digitransformationsummit.com/malaysia/

Summit Agenda: Technology Priorities Shaping 2026

Delivered through expert-led keynotes, high-impact panel discussions, and documented case studies, the Summit agenda will address the technology priorities most consequential to enterprise leaders this year:

Artificial Intelligence & Machine Learning Embedding intelligent decision-making and automation across core business functions — from supply chain to customer experience to financial operations.

Web 3.0 & Emerging Technologies Navigating decentralized innovation and unlocking new digital ecosystems with long-term enterprise relevance.

Internet of Things (IoT) Advancing operational connectivity and efficiency across industries through integrated sensor and data infrastructure.

Quantum Computing Examining the practical and strategic implications of the next frontier in computational capability.

Cybersecurity & Data Protection Strengthening enterprise digital resilience against an increasingly sophisticated and expansive threat landscape.

Cloud & Scalable Infrastructure Building the foundational agility, continuity, and scalability demanded by modern enterprise growth.

Digital Culture & Transformation Strategy Developing the leadership frameworks and organizational behaviours that sustain transformation well beyond initial implementation.

Data-Driven Decision Making Harnessing analytics to convert raw data into competitive intelligence and measurable business outcomes.

About Exito Media Concepts

Exito — the word for success — is both the name and the operating philosophy of one of the world’s most active B2B events and media organizations. Over 16 years, Exito has built a reputation for delivering 240+ conferences annually across technology, digital transformation, cybersecurity, healthcare, and emerging enterprise sectors worldwide.

Every Exito event is defined by meticulous agenda curation, access to world-class speaker communities, and a commitment to market-driven insight that translates directly into strategic value for attendees, sponsors, and partners. The result is a global platform trusted by thousands of senior executives to inform their most consequential decisions.

Media Contact
Prakruthi Nayaka
Media and PR Executive, Exito Media Concepts
Email: prakruthi.nayaka@exito-e.com
Website: https://digitransformationsummit.com/malaysia/

Doubleview Gold Corp. Announces Filing of Preliminary Economic Assessment Technical Report for the Hat Project

Marie Jones
-
0
Doubleview Gold Corp. Announces Filing of Preliminary Economic Assessment Technical Report for the Hat Project

Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (“Doubleview” or the “Company”) is pleased to announce that it has filed the independent National Instrument 43-101 Technical Report entitled “Preliminary Economic Assessment of the Hat Polymetallic Project, British Columbia, Canada” (the “Technical Report”) on SEDAR+ at www.sedarplus.ca and it can also be viewed on the Company’s website at www.doubleview.ca. The Technical Report supports the positive Preliminary Economic Assessment (“PEA”) results for the Company’s 100%-owned Hat polymetallic porphyry project (“Hat” or the “Project”), located in northwestern British Columbia, as announced on March 2, 2026 and clarified on March 23, 2026.

The PEA demonstrates robust project economics for the Hat Project, including:

NPV:

  • After-tax NPV(5%) of C$6.73 billion and IRR of 23% at Consensus Metal Prices
  • After-tax NPV(5%) of C$13.53 billion and IRR of 39% at Spot Metal Prices

NPV Including scandium and the associated processing circuit:

  • After-tax NPV(5%) of C$7.27 billion and IRR of 19% at Consensus Metal Prices
  • After-tax NPV(5%) of C$14.85 billion and IRR of 32% at Spot Metal Prices

Three processing scenarios were evaluated-Scenario A1 (A1) a Cu-Au-Ag-Co flotation base case using current testwork recoveries1, Scenario A2 (A2), the same base case using expected recoveries1, and Scenario B (B), a Cu-Au-Ag-Co flowsheet with an added hydrometallurgical circuit and scandium recovery circuit, with results indicating the Project is financially attractive even without the scandium component.

Highlights:

  • Robust Project Economics: The PEA demonstrates a high-margin operation with an After-Tax NPV(5%) of C$4.96 billion (A1), C$6.73 billion (A2), or C$7.27 billion (B), and an IRR of 19% (A1), 23% (A2), or 19% (B) at analyst consensus metal prices2. Using a spot-price scenario3, the Project delivers a compelling after-tax NPV(5%) of C$11.05 billion (A1), C13.53 billion (A2), or C$14.85 billion (B) and an IRR of 34% (A1), 39% (A2), or 32% (B).
  • Sensitivity Highlight: Project economics show the greatest leverage to overall metal prices, with NPV (5%) ranging from C$3.2 billion to C$10.2 billion (IRR: 14%-32%) at ±20% on all metals; even under additional +20% CAPEX and +20% OPEX sensitivities, applied on top of a 25% contingency already embedded in the base case, all scenarios deliver IRRs of 16% or better, and Scenario B provides additional scandium oxide upside with NPV(5%) of C$6.5 billion-C$8.1 billion (IRR: 18%-20%) at ±40% metal price.
  • Scale and Longevity: The mine plan supports a multi-decade life of 25 years at a 120,000 tonnes-per-day processing rate, underpinned by a resource base of 609 Mt at 0.43% CuEq4 in the Measured and Indicated categories and 503 Mt at 0.41% CuEq4 in the Inferred category.
  • High-Output Production Profile B: Envisioned as a conventional large-scale open-pit operation, the Project is expected to produce an average of over 74 kt of copper, 254 koz of gold, 376 koz of silver and 2.7 kt of cobalt annually during the first 10 years, with life-of-mine (LOM) average production of 67.6 kt Cu, 217 koz Au, 348 koz Ag, 2.5 kt Co, and 128 tonnes of scandium oxide per year. (NOTE: based on publicly reported 2024 North American cobalt mine production of approximately 3,800-4,000 tonnes (Natural Resources Canada; U.S. Geological Survey), the projected cobalt output is estimated to represent approximately 69% of current regional mined supply).
  • Strategic Importance for Critical Minerals: The Project is positioned as a primary North American source of copper, scandium, and cobalt. With approximately 2.42 billion pounds of copper, 80 million pounds of cobalt and 2,415 tonnes of scandium oxide contained5 in the Measured and Indicated categories, the Project represents an important discovery of critical minerals.
  • Stable, Supportive Jurisdiction: Located in a premier mining district in British Columbia, the Project benefits from a stable regulatory environment. The Company is committed to engaging with local First Nations in a respectful manner and to working toward positive and constructive relationships as the Project advances.
  • Catalyst for Development: The PEA serves as the technical foundation for an immediate transition into a Pre-Feasibility Study (PFS), providing a clear roadmap for early works and permitting activities in 2026 and 2027.

Farshad Shirvani, President and CEO of Doubleview Gold Corp., commented: “The filing of the full PEA Technical Report solidifies the robust economics outlined in March. With an after-tax NPV(5%) reaching up to C$7.27 billion at consensus prices and up to C$14.85 billion at spot prices, we believe the Hat Project is emerging as a Tier 1 asset. It is a large-scale, long-life polymetallic opportunity in a premier jurisdiction with strong exposure to critical metals including copper, scandium and cobalt. We look forward to advancing this strategic asset toward pre-feasibility while continuing to unlock value from its copper, gold, scandium and cobalt potential.”

The Company cautions that the PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

Qualified Persons

The Technical Report was prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects. The scientific and technical information contained in this news release has been reviewed and approved by the following Qualified Persons, each responsible for their respective areas of the Technical Report:

  • Tomasz Wawruch – Geology and Mineral Resource Estimate
  • Shervin Teymouri – Mining engineering, capital and operating cost estimates, financial analysis
  • Andrew Carter – Metallurgical testwork, recovery assumptions, and process metallurgy
  • Andre de Ruijter – Process design, plant engineering, and process capital and operating costs
  • Franky Li – Tailings management and tailings storage facility design
  • Jayesh Rami – Site infrastructure, civil works, access roads, and supporting facilities

Doubleview acknowledges that the Project is located on the traditional territories of the Tahltan Nation and the Taku River Tlingit First Nation, and recognizes their enduring relationship to and stewardship of the land and waters. Doubleview is committed to respectful, transparent, and ongoing engagement with First Nations and local communities whose territories overlap the Project area and access routes, with a focus on protecting water and the environment and advancing responsible development.

Readers are encouraged to review the full Technical Report on the Company’s website at www.doubleview.ca and on SEDAR+ at www.sedarplus.ca for complete details, assumptions, risks, sensitivities, and qualifications.

About Doubleview Gold Corp.

Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX Venture Exchange (TSXV: DBG), the OTCQB (DBLVF), the Berlin Stock Exchange (GER: A1W038), and the Frankfurt Stock Exchange (1D4). Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties-collectively critical minerals-and through the application of advanced, state-of-the-art exploration methods. Doubleview’s portfolio of strategic properties provides diversification and mitigates investment risk.

On behalf of the Board of Directors,

Farshad Shirvani
President & CEO

On behalf of the Board of Directors,

Farshad Shirvani, President & Chief Executive Officer

For further information please contact:

Doubleview Gold Corp
Vancouver, BC Farshad Shirvani
President & CEO

Institutional Line: (604) 607-5470

T: (604) 678-9587
E: corporate@doubleview.ca

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain of the statements made and information contained herein may constitute “forward-looking information.” In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292439

Datavault AI and AgSensor Solutions Announce Consulting Partnership to Tokenize High-Value Agricultural Data Assets

Marie Jones
-
0

Collaboration to Identify and Monetize Soil, Carbon, and Regenerative Agriculture Data for Global Exchange

Datavault AI Inc. (Datavault AI or the Company) (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, and AgSensor Solutions, LLC (AgSensor) today announced the closing of a definitive consulting partnership agreement to identify, value, and tokenize high-value agricultural data assets.

The partnership enables Datavault AI to leverage AgSensor’s deep domain expertise in the agricultural technology sector to source and vet companies with significant data assets suitable for the Company’s patented Information Data Exchange® (“IDE”), DataScore®, and DataValue® blockchain tokenization platforms. The consulting partnership targets key segments including soil sensing, carbon and sustainability data, agricultural IoT platforms, and regenerative agriculture environmental, social, and governance data firms.

By integrating AgSensor’s specialized industry knowledge with Datavault AI’s monetization infrastructure, the companies aim to create a new class of liquid, transparent digital assets derived from the $5 trillion global agricultural economy1. This initiative provides agricultural producers and technology providers with a compliant pathway – consistent with applicable securities, data privacy, and anti-money-laundering regulations – to unlock the latent value of their data while offering investors exposure to critical sustainability and food security metrics.

Nathaniel T. Bradley, CEO of Datavault AI, stated: “Our partnership with AgSensor Solutions is a pivotal step in expanding our RWA tokenization strategy into the vital agricultural sector. Data is the new crop for the modern farmer, and by applying our patented valuation and exchange technologies to soil and sustainability metrics, we are creating a transparent marketplace for agricultural intelligence. This consulting partnership ensures that high-value ag-data is properly qualified and positioned for global monetization.”

Michael J. DeSa, Co-Founder and CEO of AgSensor, added: “Partnering with Datavault AI allows us to bridge the gap between advanced agricultural sensing and the digital economy. There is an immense volume of high-quality data being generated in the field that remains undervalued. Through this agreement, we are providing the industry with the tools to tokenize these assets, driving new revenue streams for regenerative practices and enhancing the overall value of the agricultural data ecosystem.”

The strategic alignment focuses on sourcing prospects with high-value data assets, refining product positioning for the agricultural market, and facilitating the integration of these assets into Datavault AI’s product lines. This transaction further solidifies Datavault AI’s leadership in tokenizing diverse real-world assets and establishes a benchmark for the valuation and exchange of strategic agricultural data.

1 According to the Food and Agriculture Organization of the United Nations (FAO), the gross value of global primary agricultural production exceeds $5 trillion annually. Source: World Bank/FAO (2024), https://blogs.worldbank.org/en/voices/do-costs-global-food-system-outweigh-its-monetary-value

About Datavault AI Inc.
Datavault AI™ (NASDAQ:DVLT) is a pioneer in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform delivers comprehensive solutions across its Acoustic Sciences and Data Sciences divisions. Datavault AI’s Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless, high-definition sound transmission, including intellectual property covering audio timing, synchronization, and multi-channel interference cancellation.

The Data Science Division harnesses Web 3.0 and high-performance computing to enable experiential data perception, valuation, and secure monetization. The platform serves multiple industries, including sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more.

The IDE enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. Datavault AI’s technology suite is fully customizable and includes AI and machine learning automation, third-party integration, detailed analytics, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more at www.datavaultsite.com.

About AgSensor Solutions
AgSensor Solutions is a strategic consultancy specializing in the identification and optimization of agricultural technology and data assets. The firm focuses on connecting high-value agricultural data providers with advanced monetization and exchange platforms to drive innovation in soil health, carbon sequestration, and sustainable farming. Learn more at www.agsensorsolutions.com.

Forward-Looking Statements: This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. Such forward-looking statements include, but are not limited to, statements regarding future events, the expected benefits of the consulting partnership with AgSensor, anticipated suitability of the Company’s proprietary IDE, DataScore®, and DataValue® platforms to digitize ownership interests in the agriculture sector through blockchain-based tokenization, and expected operational, technical, and commercial outcomes of the Company’s commercial strategy, and the projected direction and market impacts of regulatory changes with respect to digital assets.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the ability of the Company and AgSensor to identify, value and tokenize agricultural data assets; the performance, timing, or success of the deployment of the Company’s proprietary IDE, DataScore®, and DataValue® platforms; changes in market demand for Datavault AI’s services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov.

The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments it may make.

Media Contact
marketing@dvlt.ai

Investor Contact
Edward Barger
VP, Investor Relations
ir@dvlt.ai
ebarger@dvlt.ai

SOURCE: Datavault AI Inc

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Marie Jones
-
0

– Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations
– Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization
– Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

Wellgistics Health, Inc. (NASDAQ:WGRX) (Wellgistics or the Company), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech’s wholly owned subsidiary, Kare Rx Hub, LLC (KareRx), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.

The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations’ technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx’s digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.

Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, “This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx’s provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively.”

The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.

Mital Panera, Founder and Chief Executive Officer of KareRx, added, “KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics’ technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks.”

The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.

The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the “Wellgistics Pharmacy Network”) and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC
Kare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical ‘lite’ branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical ‘lite’ products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America’s 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America’s 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.

123...2,066Page 1 of 2,066